February 7, 2019 – researchers from Johns Hopkins said the active ingredient in hallucinogenic mushrooms – psilocybin – has low abuse potential, and could reduce psychological distress and opioid abuse potential they would recommend reclassifying psilocybin from a schedule I drug – one that has no known medical potential – to a schedule IV drug – one that has low potential for abuse and dependence.
ONE STEP WONDER – Nov. 13, 2024 - Weight loss drugs such as Ozempic and…
ALWAYS WITH YOU – Nov. 2, 2024 - Archaeologists have uncovered a previously unknown effect…
TURN OFF CNN – Nov. 7, 2024 - At Toshikazu Kawaguchi’s book signings, it’s not…
86ed AGAIN? – NOV. 4, 2024 - Two previous rounds of employee cuts in September…
BY A NOSE – Nov. 5, 2024 - Thoroughbred owner and recovering alcoholic Gino Roncelli…
VIDEO – NO VALUE AT ALL – Nov. 4, 2024 - It all started innocently…